Aleplasinin is an orally active, potent, BBB-penetrated and selective SERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-β (Aβ) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer's disease research.
Molecular Weight | 425.52 |
Formula | C28H27NO3 |
CAS Number | 481629-87-2 |
Form | Solid |
Solubility (25°C) | DMSO 200 mg/mL (ultrasonic) |
Storage | 4°C, protect from light |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related PAI-1 Products |
---|
Glutaryl-Gly-Arg-AMC
Glutaryl-Gly-Arg-AMC is a peptide substrate of urokinase plasminogen activator (uPA). |
GGACK
GGACK (H-Glu-Gly-Arg-CMK) is an irreversible substrate-like serine protease urokinase-type plasminogen activator (uPA) inhibitor. |
PPACK
PPACK is a plasminogen activator (rt-PA) inhibitor. |
Anecortave acetate
Anecortave acetate is a potent ocular vascular inhibitor that inhibits angiogenic factor-induced neointima formation and also increases fibrinogen activator inhibitor 1 (PAI-1) mRNA expression.Anecortave acetate can be used in studies related to ocular neovascularization diseases. |
SK-216
SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.